This program aims to help clinicians better identify clinical presentation features of atopic dermatitis (AD) warranting a timely and accurate differential diagnosis; recognize patients for whom biologic therapies should be considered as part of treatment plans for the management of moderate-to-severe AD, and coordinate with specialists to provide patient-specific, long-term care for moderate-to-severe AD.

RELEASED DATE: August 29, 2025
EXPIRATION DATE: August 29, 2026

This enduring educational activity will help healthcare professionals expand their knowledge and skills in managing prurigo nodularis through case-based learning and expert-led discussions. Participants will gain a deeper understanding of evidence-based practices, diagnostic approaches, and treatment options to improve patient outcomes in the management of this chronic skin condition.

RELEASED DATE: January 31, 2025
EXPIRATION DATE: January 31, 2026

Upon the completion of this program, attendees should be able to:

• Apply up-to-date guidance on the initiation and use of systemic immunosuppressants and immunomodulators in patients with atopic dermatitis during the COVID-19 pandemic
• Assess the severity of atopic dermatitis and select appropriate treatment options for patients who require intensified therapy
• Review the mechanism of action, efficacy and safety of systemic treatments for atopic dermatitis in pediatric and adult patients

The goal of this program is to enhance learners’ familiarity with the roles of key drivers of bullous pemphigoid (BP) that inform diagnosis and potential treatment targets. Learners will gain the ability to achieve a timely and accurate diagnosis of BP, including knowing how and when to refer to specialists. They will also have increased awareness of the need for improved treatment options for BP and awareness of the clinical profiles of novel treatment options for BP targeting different immune pathways.

RELEASED DATE: February 13, 2025
EXPIRATION DATE: March 06, 2026

This enduring virtual activity targets healthcare gaps related to the diagnosis, treatment, and individualized management of AD, impacting outcomes through identifying burdens affecting quality of life, assessing disease severity when considering topical vs systemic intervention, and utilizing strategies in shared decision-making when determining guideline-based care.

This enduring virtual activity targets healthcare gaps related to the treatment and management of AD in urban communities, impacting outcomes through identifying determinants that impact health in urban communities, implementing strategies in disease severity assessment across varying skin tones, and guideline-based care.

• Develop treatment regimens that address the immunological and neural components of prurigo nodularis (PN)
• Integrate patient-specific factors, such as quality of life and comorbidities, into the selection of treatment options for the management of PN
• Assess clinical trial data on the efficacy and safety of emerging therapies for the treatment of PN

This enduring TeleECHO educational series focuses on the multiple ways in which patient quality of life is impaired by atopic dermatitis (AD) and the latest evidence on key treatment approaches that may provide timely relief, even in the most complex of cases. Engage with expert discussion to learn more about the benefits of patient-specific treatment strategies and ways to leverage the full range of treatment options, including biologic therapies to improve patient outcomes.

RELEASED DATE: November 27, 2024
EXPIRATION DATE: November 27, 2025